Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
About this item
Full title
Author / Creator
van der Heijden, Michiel S. , Sonpavde, Guru , Powles, Thomas , Necchi, Andrea , Burotto, Mauricio , Schenker, Michael , Sade, Juan Pablo , Bamias, Aristotelis , Beuzeboc, Philippe , Bedke, Jens , Oldenburg, Jan , Chatta, Gurkamal , Ürün, Yüksel , Ye, Dingwei , He, Zhisong , Valderrama, Begoña P. , Ku, Ja Hyeon , Tomita, Yoshihiko , Filian, Jeiry , Wang, Lily , Purcea, Daniela , Patel, Miraj Y. , Nasroulah, Federico and Galsky, Matthew D.
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with urothelial carcinoma, the addition of nivolumab to platinum-based chemotherapy resulted in longer median overall survival than platinum-based chemotherapy alone (21.7 months vs. 18.9 months).
Alternative Titles
Full title
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Authors, Artists and Contributors
Author / Creator
Sonpavde, Guru
Powles, Thomas
Necchi, Andrea
Burotto, Mauricio
Schenker, Michael
Sade, Juan Pablo
Bamias, Aristotelis
Beuzeboc, Philippe
Bedke, Jens
Oldenburg, Jan
Chatta, Gurkamal
Ürün, Yüksel
Ye, Dingwei
He, Zhisong
Valderrama, Begoña P.
Ku, Ja Hyeon
Tomita, Yoshihiko
Filian, Jeiry
Wang, Lily
Purcea, Daniela
Patel, Miraj Y.
Nasroulah, Federico
Galsky, Matthew D.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2881247997
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2881247997
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2309863
